



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 016994-012710US
Client Ref. No.: 00180-US-01

On Oct 10, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: Paula Faurer Sealey

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

van Bree et al.

Application No.: 09/454,711

Filed: December 6, 1999

For: TREATMENT OF POMPE'S
DISEASE

Examiner: F. Prats

Art Unit: 1651

COMMUNICATION UNDER 1.821-1.825

AND

AMENDMENT

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In order to comply with Requirements for patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows:

IN THE SPECIFICATION:

Please replace the paragraph beginning on page 4, line 25, with the following amended paragraph:

Fig. 1: A transgene containing acid α -glucosidase cDNA. The α 1-casein exons are represented by open boxes; α -glucosidase cDNA is represented by a shaded box. The α 1-casein intron and flanking sequences (SEQ ID NOS:2 and 3) are represented by a thick line. A

B2